Tumor Biology

, Volume 36, Issue 8, pp 6497–6505 | Cite as

Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12

  • Zongtao Xie
  • Liming Cai
  • Runsheng Li
  • Jinyu Zheng
  • Hongyan Wu
  • Xiaoqi Yang
  • Hu Li
  • Zhiqiang Wang
Research Article

Abstract

microRNAs are small, non-coding RNAs that contribute into various biological processes during cancer progression. However, the potential role of miR-489 in the development of Non-Small Cell Lung Cancer (NSCLC) is not demonstrated. In present study, miR-489 was down-regulated both in tumor tissues and cells. Inhibition of miR-489 promoted cells invasion by using an invasion assay. Furthermore, miR-489 could regulate SUZ12 as shown by luciferase reporter and Western blot assays. Aberrant miR-489 expression could regulate the molecular changes (E-cadherin, N-cadherin, and Vimentin) of epithelial mesenchymal transition (EMT). In conclusion, our study revealed that miR-489 may play an essential role in the progression of NSCLC.

Keywords

miR-489 SUZ12 Invasion EMT NSCLC 

Notes

Acknowledgments

We thank our mentor in our lab for critical reading of the manuscript.

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61:69–90.Google Scholar
  2. 2.
    Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000-02 period analysis of eurocare-4 data. Lancet Oncol. 2007;8:784–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Osada H, Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene. 2002;21:7421–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Cheng L, Yang T, Kuang Y, Kong B, Yu S, Shu H, et al. Microrna-23a promotes neuroblastoma cell metastasis by targeting cdh1. Oncol Lett. 2014;7:839–45.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Miao L, Xiong X, Lin Y, Cheng Y, Lu J, Zhang J, et al. Mir-203 inhibits tumor cell migration and invasion via caveolin-1 in pancreatic cancer cells. Oncol Lett. 2014;7:658–62.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Esquela-Kerscher A, Slack FJ. Oncomirs - micrornas with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMedGoogle Scholar
  7. 7.
    Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, et al. Microrna-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting myb. Cancer Lett. 2014;347:65–74.CrossRefPubMedGoogle Scholar
  8. 8.
    8 Yang Y, Meng H, Peng Q, Yang X, Gan R, Zhao L, Chen Z, Lu J, Meng QH: Downregulation of microrna-21 expression restrains non-small cell lung cancer cell proliferation and migration through upregulation of programmed cell death 4. Cancer gene therapy 2014.Google Scholar
  9. 9.
    Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, Gel B, et al. Mir-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Lei L, Huang Y, Gong W. Mir-205 promotes the growth, metastasis and chemoresistance of nsclc cells by targeting pten. Oncol Rep. 2013;30:2897–902.PubMedGoogle Scholar
  11. 11.
    Xu TP, Zhu CH, Zhang J, Xia R, Wu FL, Han L, et al. Microrna-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pacific J Cancer Prevent : APJCP. 2013;14:7085–90.CrossRefGoogle Scholar
  12. 12.
    Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for ezh2 histone methyltransferase activity. EMBO J. 2004;23:4061–71.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of mir-200 inhibition of suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010;39:761–72.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, et al. Suz12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing hrk. Molec Cancer Res : MCR. 2012;10:1462–72.CrossRefGoogle Scholar
  15. 15.
    Martin-Perez D, Sanchez E, Maestre L, Suela J, Vargiu P, Di Lisio L, et al. Deregulated expression of the polycomb-group protein suz12 target genes characterizes mantle cell lymphoma. Am J Pathol. 2010;177:930–42.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Liu C, Shi X, Wang L, Wu Y, Jin F, Bai C, et al. Suz12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol : J Int Soc Oncodev Biol Med. 2014;35:6073–82.CrossRefGoogle Scholar
  17. 17.
    Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, Labarge MA, You L, Kogan SC, Gray JW, Mao JH, Wei G: Cul4a induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating zeb1 expression. Cancer Res 2013.Google Scholar
  18. 18.
    Liu J, Ruan B, You N, Huang Q, Liu W, Dang Z, et al. Downregulation of mir-200a induces emt phenotypes and csc-like signatures through targeting the beta-catenin pathway in hepatic oval cells. PLoS One. 2013;8:e79409.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMedGoogle Scholar
  20. 20.
    da Silva SD, Alaoui-Jamali MA, Soares FA, Carraro DM, Brentani HP, Hier M, et al. Twist1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target. Cancer. 2014;120:352–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: Cancer J Clin. 2013;63:11–30.Google Scholar
  22. 22.
    Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth g.H.A. Clowes memorial award lecture. Cancer Res. 1990;50:6130–8.PubMedGoogle Scholar
  23. 23.
    Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microrna expression profiling in non small cell lung cancer. Lung Cancer. 2013;81:388–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the mirna-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates emt is involved in cancer progression. Neoplasia. 2013;15:180–91.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ouyang H, Gore J, Deitz S, Korc M: Microrna-10b enhances pancreatic cancer cell invasion by suppressing tip30 expression and promoting egf and tgf-beta actions. Oncogene 2013.Google Scholar
  26. 26.
    Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A: Mir-134/487b/655 cluster regulates tgf-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting magi2 in lung adenocarcinoma cells. Mol Cancer Ther 2013.Google Scholar
  27. 27.
    Benoit YD, Witherspoon MS, Laursen KB, Guezguez A, Beausejour M, Beaulieu JF, et al. Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp Cell Res. 2013;319:1463–70.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Zongtao Xie
    • 1
  • Liming Cai
    • 2
  • Runsheng Li
    • 2
  • Jinyu Zheng
    • 3
  • Hongyan Wu
    • 3
  • Xiaoqi Yang
    • 4
  • Hu Li
    • 5
  • Zhiqiang Wang
    • 1
  1. 1.Department of Thoracic and Cardiovascular Surgery, Affiliated Hospital of Jiangnan UniversityThe Forth People’s Hospital of Wuxi CityWuxiChina
  2. 2.Department of Respiratory Medicine, Affiliated Hospital of Jiangnan UniversityThe Forth People’s Hospital of Wuxi CityWuxiChina
  3. 3.Department of Pathology, Nanjing Drum Tower HospitalThe Affiliated Hospital of Nanjing University Medical SchoolNanjingChina
  4. 4.Department of Orthopedics, Affiliated Hospital of Jiangnan UniversityThe Forth People’s Hospital of Wuxi CityWuxiChina
  5. 5.Department of Plastic Surgery, Affiliated Hospital of Jiangnan UniversityThe Forth People’s Hospital of Wuxi CityWuxiChina

Personalised recommendations